Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.
The metabolism of pancreatic cancer cells is altered by the anticancer activity of CDK4/6 inhibitors. Researchers hope this biologic vulnerability could be exploited to treat pancreatic cancer.
Dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations have been suggested by the largest analysis of breast cancer cell function to date.
Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may halt disease progression in certain patients.
Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.
Lung cancers with KRAS-related gene mutations might benefit from a triple therapy regimen of 2 experimental drugs plus radiation therapy.
Palbociclib, a new oral treatment for certain types of breast cancer, demonstrates potential as a treatment for other types of cancer as well.
Researchers identified a protein that is essential for MYC to cause cancer in mouse models, and they believe, could be a target for anticancer therapy.
Mandatory tumor tissue specimens and associated analyses for clinical trial participation appear to be a significant barrier to clinical trial enrollment and may delay treatment.
The evolution of drug resistance in a patient with lung cancer was demonstrated in a recent case. In the case, molecular analysis of a metastatic lesion revealed resistance to a third targeted therapy; however, the new mutation restored tumor response to the first targeted therapy used.
Findings from a recently published study point to the enzyme casein kinase 1δ (CK1δ), a critical regulator of growth, as a novel and highly vulnerable therapeutic target in hard-to-treat subtypes of breast cancer.
Certain drugs currently used to treat breast, ovarian, and pancreatic cancers could also be used to treat certain gastric cancers with a particular genomic molecular fingerprint.
Researchers identified two new cancer-causing gene mutations that could lead to more targeted and effective treatments for certain lung and prostate cancers.
Genome sequencing database provides easy access to information on clinically important cancer gene mutationsSeptember 25, 2015
Researchers designed an online database, the Cancer Driver Log (CanDL) to help oncologists and other health care professionals identify key mutations that drive tumor growth in tissues.
Scientists have discovered that magnetic resonance imaging (MRI) scanners, normally used to produce images, can be used direct tumor therapies to specific target sites.
Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
New research has identified as few as nine genetic features would need to be tested to identify high-risk patients who might benefit from intensive myeloma treatment.
A new tool predicts what genetics are truly driving the cancer in any population of cells and helps the user choose the best kinase inhibitor to address the issue.
Targeted therapy for skin cancer is effective in patients with sonic hedgehog (SHH) subtype of medulloblastomaAugust 26, 2015
A targeted therapy already used to treat advanced skin cancer has also been found to be effective when used to treat the most common subtype of adult medulloblastoma.
A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by targeted treatment.
New research indicates that treating patients with esophageal cancer with proton therapy produces fewer toxic side effects than utilizing older radiation therapies.
Researchers have reported safely using immune cells grown from patients' own bone marrow to treat multiple myeloma, according to clinical trial data.
Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
Researchers have quantified the mutational profiles for cell clusters in individual colorectal cancer tumors that have metastasized.
A new strategy targeting a protein that drives melanoma growth has been proposed in a research report.
Trials results indicate that the pioneering drug olaparib, which targets inherited mutations, can be beneficial for men with prostate cancer.
Accurate administration of proton radiotherapy in mobile organs, such as the lung, can be difficult, but researchers have developed a model that will allow for better beam targeting.
Investigators have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, a discovery that may lead to a new melanoma target or prompt new designs for treatment.
A new triple combination therapy has shown signs that it can more effectively control advanced melanoma that previous, dual-therapy combinations.
- Understanding Drug Naming Nomenclature
- Prostate-Specific Antigen (PSA) Test (Fact Sheet)
- CDK4/6 Inhibitors Exploit a Unique Vulnerability in Pancreatic Cancer
- Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed
- Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma
- Low-income Breast Cancer Survivors Benefit From Personalized Survivorship Care Plans
- Understanding Drug Naming Nomenclature
- Nurse Navigators Key to Seamless Transition From Pediatric to Adult Survivorship Care
- Common Painkiller Has Anticancer Effects
- Palliative Care is Cost Effective for Cancer Patients, and Increases With Comorbidities
- Chemotherapy-related Bone Loss in Children With ALL Occurs Earlier Than Previously Assumed
- Data Analysis Shows 8-week Chemoradiotherapy-to-Surgery Timeline Achieves Optimal Tumor Response
- Exercise During Neoadjuvant CRT Less Difficult Than Anticipated for Rectal Cancer
- Early Onset of Everolimus Adverse Events Requires Thorough Patient Education
- Nanoparticle System Uses Light Waves to Target Release Site of Drug
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|